Sera Prognostics, Inc. (SERA)
Nasdaq · Services-Medical Laboratories · Services · CIK 1534969 · fiscal year ends in Dec
Closing price $2.05 on 30 Oct 2026; 52-week range $1.59 to $3.69.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $70.0K
- Revenue growth
- -35.2%
- Net income, last twelve months
- -$33.2M
- Earnings per share
- -$0.67
- Gross margin
- -150.0%
- Operating margin
- -53282.9%
- Net margin
- -47475.7%
- Free cash flow
- -$28.1M
- Return on equity
- -56.0%
- Market value
- $103.5M
- Cash
- $4.4M
- Debt
- $0
- Debt to equity
- 0.00
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $81.0K | -$36.5M | -$31.9M | -$0.67 | -$26.3M | 10-K filed 18 Mar 2026 |
| FY2024 | 31 Dec 2024 | $77.0K | -$36.6M | -$32.9M | -$0.99 | -$14.2M | 10-K filed 19 Mar 2025 |
| FY2023 | 31 Dec 2023 | $306.0K | -$39.8M | -$36.2M | -$1.16 | -$27.3M | 10-K filed 19 Mar 2025 |
| FY2022 | 31 Dec 2022 | $268.0K | -$45.7M | -$44.2M | -$1.43 | -$35.4M | 10-K filed 22 Mar 2023 |
| FY2021 | 31 Dec 2021 | $82.0K | -$35.4M | -$35.0M | -$2.33 | -$32.9M | 10-K filed 29 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $30.0K | -$9.1M | -$0.18 |
| Q1 FY2026 | 31 Mar 2026 | $14.0K | -$8.4M | -$0.17 |
| Q4 FY2025 | 31 Dec 2025 | $10.0K | -$7.9M | -$0.16 |
| Q3 FY2025 | 30 Sep 2025 | $16.0K | -$7.8M | -$0.16 |
| Q2 FY2025 | 30 Jun 2025 | $17.0K | -$8.0M | -$0.16 |
| Q1 FY2025 | 31 Mar 2025 | $38.0K | -$8.2M | -$0.20 |
| Q4 FY2024 | 31 Dec 2024 | $24.0K | -$8.6M | -$0.25 |
| Q3 FY2024 | 30 Sep 2024 | $29.0K | -$7.9M | -$0.24 |
Company events
The newest 8-K filings of 55 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 19 Aug 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 12 Aug 2026 | 8-K | Results | 2.02, 9.01 |
| 30 Jun 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 4 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 1 Jun 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 6 May 2026 | 8-K | Results | 2.02, 9.01 |
| 18 Mar 2026 | 8-K | Results | 2.02, 9.01 |
| 8 Jan 2026 | 8-K | Investor update | 7.01, 9.01 |
| 7 Jan 2026 | 8-K | Investor update | 7.01, 9.01 |
| 24 Nov 2025 | 8-K | Investor update | 7.01, 9.01 |
| 13 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 5 Sep 2025 | 8-K | Investor update | 7.01, 9.01 |
Every filing
The newest filings with the SEC of 136 held.
| Filed | Form | Period |
|---|---|---|
| 19 Aug 2026 | 8-K | 14 Aug 2026 |
| 12 Aug 2026 | 10-Q | 30 Jun 2026 |
| 12 Aug 2026 | 8-K | 12 Aug 2026 |
| 30 Jun 2026 | 8-K | 25 Jun 2026 |
| 4 Jun 2026 | 8-K | 4 Jun 2026 |
| 1 Jun 2026 | DEFA14A | – |
| 1 Jun 2026 | 8-K | 26 May 2026 |
| 6 May 2026 | 10-Q | 31 Mar 2026 |
| 6 May 2026 | 8-K | 6 May 2026 |
| 24 Apr 2026 | ARS | 31 Dec 2025 |
| 24 Apr 2026 | DEFA14A | – |
| 24 Apr 2026 | DEF 14A | 23 Apr 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 12 Oct 2026 | Inglis Tiffany Eul Davis, Chief Medical Officer | Sale outside a trading plan | 8,024 | $2.03 | $16.3K | 83,565 | 13 Oct 2026 |
| 10 Sep 2026 | Anderson Dyaarl Lee Jr., Chief Commercial Officer | Sale outside a trading plan | 1,800 | $2.00 | $3.6K | 76,198 | 11 Sep 2026 |
| 10 Sep 2026 | Lindgardt Zhenya, Chief Executive Officer | Sale outside a trading plan | 7,022 | $2.00 | $14.0K | 837,848 | 11 Sep 2026 |
| 10 Sep 2026 | Inglis Tiffany Eul Davis, Chief Medical Officer | Sale outside a trading plan | 486 | $2.00 | $972 | 91,589 | 11 Sep 2026 |
| 10 Sep 2026 | Jackson Benjamin, General Counsel | Sale outside a trading plan | 2,190 | $2.00 | $4.4K | 159,566 | 11 Sep 2026 |
| 8 Sep 2026 | Lindgardt Zhenya, Chief Executive Officer | Sale outside a trading plan | 20,139 | $2.00 | $40.3K | 844,870 | 9 Sep 2026 |
| 11 Jun 2026 | Anderson Dyaarl Lee Jr., Chief Commercial Officer | Sale outside a trading plan | 4,739 | $2.01 | $9.5K | 77,998 | 15 Jun 2026 |
| 11 Jun 2026 | Aerts Austin, Chief Financial Officer | Sale outside a trading plan | 2,037 | $2.01 | $4.1K | 301,190 | 15 Jun 2026 |
| 11 Jun 2026 | Lindgardt Zhenya, Chief Executive Officer | Sale outside a trading plan | 6,990 | $2.01 | $14.1K | 865,009 | 15 Jun 2026 |
| 11 Jun 2026 | Inglis Tiffany Eul Davis, Chief Medical Officer | Sale outside a trading plan | 362 | $2.01 | $728 | 92,075 | 15 Jun 2026 |
| 11 Jun 2026 | Jackson Benjamin, General Counsel | Sale outside a trading plan | 2,179 | $2.01 | $4.4K | 161,756 | 15 Jun 2026 |
| 9 Jun 2026 | Lindgardt Zhenya, Chief Executive Officer | Sale outside a trading plan | 20,755 | $2.08 | $43.2K | 871,999 | 10 Jun 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 13 Oct 2026 | Inglis Tiffany Eul Davis, Officer | 8,024 | $16.3K | 12 Oct 2026 |
| 11 Sep 2026 | Inglis Tiffany Eul Davis, Officer | 486 | $972 | 10 Sep 2026 |
| 11 Sep 2026 | Aerts Austin, Officer | 1,509 | $3.0K | 10 Sep 2026 |
| 11 Sep 2026 | Anderson Dyaarl Lee Jr., Officer | 1,800 | $3.6K | 10 Sep 2026 |
| 11 Sep 2026 | Jackson Benjamin, Officer | 2,190 | $4.4K | 10 Sep 2026 |
| 11 Sep 2026 | Lindgardt Zhenya, Officer, Director | 7,022 | $14.0K | 10 Sep 2026 |
| 9 Sep 2026 | Aerts Austin, Officer | 13,591 | $27.2K | 8 Sep 2026 |
| 9 Sep 2026 | Lindgardt Zhenya, Officer, Director | 20,139 | $40.3K | 8 Sep 2026 |
| 15 Jun 2026 | Inglis Tiffany Eul Davis, Officer | 362 | $726 | 11 Jun 2026 |
| 15 Jun 2026 | Aerts Austin, Officer | 2,037 | $4.1K | 11 Jun 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 15 Jul 2026 | Aberdeen Group plc | 13G amended | 7.21% | 2.8M |
| 1 May 2026 | Whetstone Capital Advisors, LLC | 13G amended | 8.6% | 3.3M |
| 16 Jan 2026 | Whetstone Capital Advisors, LLC | 13G amended | 9.2% | 3.5M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 222.7K | -3.05% | 21.54 |
| 30 Sep 2026 | 229.7K | +7.4% | 13.42 |
| 15 Sep 2026 | 213.9K | -3.56% | 7.55 |
| 31 Aug 2026 | 221.8K | -1.54% | 10.45 |
| 14 Aug 2026 | 225.3K | -2.43% | 6 |
| 31 Jul 2026 | 230.9K | -4.14% | 6.43 |
| 15 Jul 2026 | 240.8K | -8.27% | 6.83 |
| 30 Jun 2026 | 262.5K | -1.02% | 6.45 |
Funds that hold it
From each fund's latest Form 13F.
56 funds held it at 30 Jun 2026: 11 added and 13 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Baker Bros. Advisors LP | 5,498,170 | $10.0M | 0 |
| Whetstone Capital Advisors, LLC | 3,306,889 | $6.0M | 0 |
| Aberdeen Group plc | 2,753,525 | $5.0M | +202,750 |
| Vivo Capital, LLC | 1,650,440 | $3.0M | 0 |
| Vanguard Capital Management LLC | 1,297,792 | $2.4M | +93,677 |
| Captrust Financial Advisors | 535,755 | $975.1K | -1,006 |
| Geode Capital Management, LLC | 348,967 | $635.5K | -14,650 |
| BlackRock, Inc. | 221,369 | $402.9K | +25,264 |
| AWM Investment Company, Inc. | 207,382 | $377.4K | 0 |
| Vanguard Fiduciary Trust Co. | 170,908 | $311.1K | +1,247 |
Peers
Companies in the same industry.
- Natera, Inc. (NTRA): revenue $2.7B, market value $59.5B
- Labcorp Holdings Inc. (LH): revenue $14.6B, market value $29.4B
- Quest Diagnostics Inc. (DGX): revenue $11.8B, market value $27.7B
- Guardant Health, Inc. (GH): revenue $1.2B, market value $23.9B
- Caris Life Sciences, Inc. (CAI): revenue $989.6M, market value $9.7B
- Grail, Inc. (GRAL): revenue $165.3M, market value $6.4B
- RadNet, Inc. (RDNT): revenue $2.3B, market value $5.8B
- BillionToOne, Inc. (BLLN): revenue $397.4M, market value $5.3B
- CareDx, Inc. (CDNA): revenue $497.4M, market value $4.6B
- Veracyte, Inc. (VCYT): revenue $561.9M, market value $4.0B